Johnson & Johnson’s Covid-19 vaccine protected macaques in a single shot

Cheryl Sanders
August 1, 2020

He said they are now ready to expand the test of the Imperial vaccine to around 300 volunteers, including some that are 75 years old.

Russian Federation has released no scientific data proving the vaccines' safety or efficacy. Shattock, who is leading vaccine research at Imperial, said that we are still studying it.

Nevertheless, Kirill Dmitriev, the head of Russia's sovereign wealth fund which is financing the Gamaleya trials, told CNN: "It's a Sputnik moment". "Russian Federation will have got there first", he added.

Since COVID-19 infections have dropped dramatically in Britain, making it hard to determine whether or not the vaccine works, Shattock said he and his colleagues are also looking to test their vaccine elsewhere.

"The Russian Defence Ministry tests the vaccine on volunteers in full compliance with the acting legislation and scientific methodological regulations, in order to prevent further risks, without any attempt to reduce the duration of the research", global news agency Sputnik reported citing the Russian government as saying.

"Critics say the country's push for a vaccine comes amid political pressure from the Kremlin, which is keen to portray Russian Federation as a global scientific force", notes the report. The vaccine will be made available for public use; however healthcare workers will be the first ones to get it.

A professor from Flinders University in Adelaide developed the vaccine, which is now the first candidate to clear phase 1 trials in Australia, The Australian has reported.

"A single-shot immunization has practical and logistical advantages over a two-shot regimen for global deployment and pandemic control, but a two-shot vaccine will likely be more immunogenic, and thus both regimens are being evaluated in clinical trials", Barouch added.

"We have 20 vaccines in clinical trials, (so) we can be pretty confident that at least two of those will work", he said. That's the approach being taken in many other countries and by other companies, claimed the Russian scientists. There are also wide concerns human testing of the vaccine is incomplete.

J&J's vaccine uses a common cold virus known as adnovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the body, causing the body to mount an immune defense against the virus.

Other reports by iNewsToday